Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.10	$1.60	$1.06 ▼ $10.16	$34.49M	1.88	232,777 shs	665,213 shs
FBIO Fortress Biotech	$1.95 +2.6%	$1.65	$1.33 ▼ $2.89	$57.66M	1.85	408,114 shs	213,206 shs
MDNA Medicenna Therapeutics		$0.29	$0.15 ▼ $0.84	$10.93M	1.3	160,047 shs	1.27 million shs
PDSB PDS Biotechnology	$1.40 +2.2%	$1.23	$0.85 ▼ $4.42	$63.99M	1.4	487,057 shs	370,153 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	0.00%	-4.35%	-23.61%	-79.28%	-85.33%
FBIO Fortress Biotech	+2.63%	+12.72%	+11.43%	+24.20%	+7.14%
MDNA Medicenna Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PDSB PDS Biotechnology	+2.19%	-10.83%	+11.11%	+5.26%	-52.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	3.6686 of 5 stars	4.5	3.0	0.0	0.0	2.2	3.3	0.6
FBIO Fortress Biotech	2.6959 of 5 stars	3.5	1.0	0.0	0.0	3.3	3.3	0.6
MDNA Medicenna Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	1.9251 of 5 stars	3.7	3.0	0.0	0.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,510.39% Upside
FBIO Fortress Biotech	3.00	Buy	$21.00	976.92% Upside
MDNA Medicenna Therapeutics	3.00	Buy	$2.50	∞ Upside
PDSB PDS Biotechnology	3.33	Buy	$9.00	542.86% Upside

Current Analyst Ratings Breakdown

Latest MDNA, PDSB, ACRV, and FBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/27/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $13.00
3/26/2025	ACRV Acrivon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/26/2025	ACRV Acrivon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
3/13/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
3/11/2025	FBIO Fortress Biotech	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $16.00
3/7/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.38 per share	N/A
FBIO Fortress Biotech	$57.78M	1.00	N/A	N/A	$0.10 per share	19.50
MDNA Medicenna Therapeutics	N/A	N/A	N/A	N/A	$0.32 per share	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$60.39M	-$2.22	N/A	N/A	N/A	N/A	-47.95%	-43.73%	8/12/2025 (Estimated)
FBIO Fortress Biotech	-$60.64M	-$2.23	N/A	N/A	N/A	-84.53%	N/A	-34.93%	8/12/2025 (Estimated)
MDNA Medicenna Therapeutics	-$7.60M	-$0.09	N/A	N/A	N/A	N/A	-42.68%	-35.17%	N/A
PDSB PDS Biotechnology	-$42.94M	-$0.94	N/A	N/A	N/A	N/A	-139.57%	-67.22%	8/12/2025 (Estimated)

Latest MDNA, PDSB, ACRV, and FBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	PDSB PDS Biotechnology	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
3/31/2025	Q4 2024	FBIO Fortress Biotech	-$0.79	-$0.26	+$0.53	-$0.26	$16.30 million	$15.12 million
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A
3/27/2025	Q4 2024	PDSB PDS Biotechnology	-$0.29	-$0.21	+$0.08	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
MDNA Medicenna Therapeutics	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	12.75	12.75
FBIO Fortress Biotech	N/A	1.23	1.06
MDNA Medicenna Therapeutics	N/A	9.57	9.57
PDSB PDS Biotechnology	0.55	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
FBIO Fortress Biotech	96.51%
MDNA Medicenna Therapeutics	12.38%
PDSB PDS Biotechnology	26.84%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
FBIO Fortress Biotech	33.40%
MDNA Medicenna Therapeutics	33.10%
PDSB PDS Biotechnology	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.36 million	28.49 million	Not Optionable
FBIO Fortress Biotech	170	29.57 million	18.39 million	Optionable
MDNA Medicenna Therapeutics	16	69.64 million	46.59 million	Not Optionable
PDSB PDS Biotechnology	20	45.71 million	33.86 million	Optionable

MDNA, PDSB, ACRV, and FBIO Headlines

Recent News About These Companies

PDS Biotechnology files to sell 9.82M shares of common stock for holders

May 28 at 2:34 AM | msn.com

PDS Biotechnology (NASDAQ:PDSB) Raised to Hold at Wall Street Zen

May 26, 2025 | americanbankingnews.com

Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to "Hold"

May 26, 2025 | marketbeat.com

Q2 EPS Estimates for PDS Biotechnology Increased by B. Riley

May 24, 2025 | marketbeat.com

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of ...

May 23, 2025 | uk.finance.yahoo.com

B. Riley Increases Earnings Estimates for PDS Biotechnology

May 23, 2025 | americanbankingnews.com

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025 | globenewswire.com

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses

May 16, 2025 | uk.investing.com

Data and sensing technology: Increases the value of PDS

May 16, 2025 | miningreview.com

PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

May 15, 2025 | finance.yahoo.com

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

EMV Capital portfolio company PDS Biotech advances cancer trial

May 15, 2025 | proactiveinvestors.co.uk

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 14, 2025 | globenewswire.com

Insights Ahead: PDS Biotechnology's Quarterly Earnings

May 14, 2025 | benzinga.com

PDS Biotechnology (PDSB) to Release Earnings on Wednesday

May 11, 2025 | marketbeat.com

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025 | globenewswire.com

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 8, 2025 | globenewswire.com

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

May 7, 2025 | globenewswire.com

Why PDS Biotechnology Corporation’s (PDSB) Stock Is Down 5.76%

May 7, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDNA, PDSB, ACRV, and FBIO Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.10 0.00 (0.00%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.10 +0.00 (+0.45%)

As of 05/29/2025 06:10 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Fortress Biotech NASDAQ:FBIO

$1.95 +0.05 (+2.63%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.96 +0.02 (+0.77%)

As of 05/29/2025 05:44 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Medicenna Therapeutics NASDAQ:MDNA

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

PDS Biotechnology NASDAQ:PDSB

$1.40 +0.03 (+2.19%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.41 +0.01 (+0.43%)

As of 05/29/2025 07:50 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time